Top Markets
Coin of the day
Kiromic BioPharma, Inc. Kiromic BioPharma, Inc.

Kiromic BioPharma, Inc.

KRBP
Clasificación en acciones #35637
Kiromic BioPharma, Inc. is a biotechnology enterprise that harnesses artificial... Kiromic BioPharma, Inc. is a biotechnology enterprise that harnesses artificial intelligence to advance allogeneic cell therapies. The company's core mission involves crafting multi-indication T-cell treatments, specifically engineered to combat solid tumors by leveraging the innate capabilities of Gamma Delta T cells. Its developmental pipeline includes ALEXIS-ISO-1, an allogeneic gamma delta CAR-T cell therapy targeting Isomesothelin, and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy designed to address PD-L1. Supporting its research and development efforts, the company holds licensing agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, maintains a collaborative partnership for R&D with Molipharma, S.R.L., and has established a strategic alliance with Leon Office (H.K.) Ltd. Founded in 2006, the entity was initially known as Kiromic, Inc. before officially changing its name to Kiromic BioPharma, Inc. in December 2019. Its operations are headquartered in Houston, Texas.
Precio por acción
$0.11
Última sincronización: 2025-05-07
Capitalización bursátil
$3.62M
Cambio (1 día)
78.86%
Cambio (1 año)
0.00%
País
US
Comercio Kiromic BioPharma, Inc. (KRBP)

Categoría

Ratio P/S de Kiromic BioPharma, Inc. (KRBP)
Ratio P/S al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Kiromic BioPharma, Inc., el ratio P/S actual (TTM) es 0. Al final de 2026, el ratio P/S era 0.
Historial del ratio P/S de Kiromic BioPharma, Inc. desde 2026 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
Not enough data for the provided dates.
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
10.17 -
US
10.13 -
NL
- -
CH
- -
KR
4.74 -
BE